2025
January
Why anti-CTLA-4 promotes better memory responses than anti-PD-1
January 22, 2025
In the clinic, anti-CTLA-4 induces more durable responses than anti-PD-1. In recent research, Mok et al. investigated possible mechanisms underlying this durability by using a variety of mouse tumor and vaccine models. They found that anti-CTLA-4 induced stronger memory responses than anti-PD-1 by preserving CD8+ T cells with high levels of TCF-1 and...
Autologous neoantigen-directed T cell therapy shows promise in clinic
January 15, 2025
While major progress has been made in targeted and immune checkpoint blockade (ICB) therapy for melanoma, many patients do not respond or their response is not durable. To investigate a new approach for these patients, Borgers et al. performed a Phase 1 study assessing targeted adoptive T cell therapy (ACT) directed against patient-specific...
What really happens when you block TIGIT and PD-L1 together
January 8, 2025
Both PD-1 and TIGIT are checkpoint molecules known to inhibit the antitumor effects of CD8+ T cells, and blocking them in combination has been shown to have synergistic immunotherapeutic effects. However, the exact mechanism and dynamics of this synergy are incompletely understood. In recent research, Nutsch, Banta, and Wu et al. utilized a...
